Actuate (ACTU) news
Recent news
Actuate Therapeutics - To sell 65,000,000 shares - SEC filing
AInvest Wire · 1d agoTrading released/resumed: (Attiu) Reason not available
Trading in the security known as "Attiu" has been temporarily halted, with the resumption date and reason for the halt not currently available to the public. Trading pauses are typically implemented to address market irregularities, ensure fair trading practices, or allow for dissemination of…
AInvest Wire · 2d agoActuate Therapeutics - To sell 50,000,000 shares at assumed price of $0.82 per share - SEC filing
Actuate Therapeutics, Inc. (NASDAQ: ACTU) has announced plans to offer 50,000,000 shares of its common stock in a public offering at an assumed price of $0.82 per share, according to a recent SEC filing. The company has also granted the underwriters a 30-day option to purchase up to an additional…
AInvest Wire · Oct 6, 2026Actuate announces promising preclinical data showing synergistic activity of elraglusib in combination with Ras inhibitors Zoldonrasib and Daraxonrasib
AInvest Wire · Sep 9, 2026Lutnick: Two years agreed to give manufacturers sufficient time to build up supply chain; no third year of relief
Lutnick: Two years agreed to give manufacturers sufficient time to build up supply chain; no third year of relief Landstar System, Inc. (NASDAQ: LSTR) has announced the rescheduling of its 2025 first quarter earnings release and conference call to May 13, 2025, from the previously planned date of…
AInvest Wire · Apr 29, 2025Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.